Vetenskapliga publikationer

2022 | 2021 | 2020 | 2019 | 2018 | 2017


2022

Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study.
https://pubmed.ncbi.nlm.nih.gov/36467453/

Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.
https://pubmed.ncbi.nlm.nih.gov/35834389/

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study.
https://pubmed.ncbi.nlm.nih.gov/35776552/

Identification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study.
https://pubmed.ncbi.nlm.nih.gov/35520278/

Association Between Inflammatory Bowel Disease and Spondyloarthritis: Findings from a Nationwide Study in Sweden.
https://pubmed.ncbi.nlm.nih.gov/35512691/

Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn’s Disease.
https://pubmed.ncbi.nlm.nih.gov/35459973/

Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
https://pubmed.ncbi.nlm.nih.gov/34999206/

Tumour necrosis factor inhibitors in Crohn’s disease and the effect on surgery rates.
https://pubmed.ncbi.nlm.nih.gov/34905282/

Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a Cryptosporidium hominisoutbreak.
https://pubmed.ncbi.nlm.nih.gov/35802626/


2021

Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
https://pubmed.ncbi.nlm.nih.gov/33340426/

Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register – a validation study.
https://pubmed.ncbi.nlm.nih.gov/33632044/


2020

A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.
https://pubmed.ncbi.nlm.nih.gov/33116900/

 

Healthcare use, work loss and total costs in incident and prevalent Crohn’s disease and ulcerative colitis: results from a nationwide study in Sweden.
https://pubmed.ncbi.nlm.nih.gov/32902894/

 

The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
https://pubmed.ncbi.nlm.nih.gov/32370571/

 

Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study.
https://pubmed.ncbi.nlm.nih.gov/32210631/


2019

Swedish Inflammatory Bowel Disease Register (SWIBREG) – a nationwide quality register.
https://www.ncbi.nlm.nih.gov/pubmed/31498717

Work Loss Before and After Diagnosis of Crohn’s Disease.
https://www.ncbi.nlm.nih.gov/pubmed/30551185

Validating surgical procedure codes for inflammatory bowel disease in the Swedish National PatientRegister.
https://www.ncbi.nlm.nih.gov/pubmed/31711471


2018

Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
https://www.ncbi.nlm.nih.gov/pubmed/30353751

Sick leave and disability pension in prevalent patients with Crohn’s disease.
https://www.ncbi.nlm.nih.gov/pubmed/30165593

Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
https://www.ncbi.nlm.nih.gov/pubmed/29102619


2017

Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
https://www.ncbi.nlm.nih.gov/pubmed/27797278

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
https://www.ncbi.nlm.nih.gov/pubmed/28362144